Gli altri portali
Notizie
Comunicati Stampa
Social News
Offerte di Lavoro
Comunicati Stampa
Sezioni
Toggle navigation
Prima pagina
Elenco
Nuovo account
Inserimento
Pannello di controllo
Modifica password
Salute e Benessere
Seleziona Categoria
Tutte le Categorie
Agricoltura
Ambiente
Arte e Cultura
Cibi e Bevande
Economia
Editoria e Media
Elettronica
Energia
Fiere ed Eventi
Industria
Information Technology
Internet
Istruzione e Formazione
Moda
Non Profit
Politica e Istituzioni
Salute e Benessere
Scienza e Tecnologia
Servizi
Società
Spettacolo
Sport
Telecomunicazioni
Trasporti
Turismo
Varie
Italiano
Inglese
Spagnolo
TFS HealthScience Unveils Asia Pacific Expansion, Elevating Patient Access and…
Dr. Bassem Saleh, Chief Executive Officer at TFS, expressed his enthusiasm for the expansion, stating, "As we extend our footprint into the APAC region, Australia emerges as a strategic focal point for establishing operations in all our business units, including Ophthalmology, Dermatology, Neurology, Oncology, and Strategic Resourcing. Australia's expanding market aligns perfectly with our vision for growth and innovation. This expansion enables us to better integrate into the APAC region…
PR Newswire
12/03/2024
CHC Shifts Biking Accessibility into Higher Gear with Official Handcycle Launch…
"We envision a more accessible, inclusive, sustainable, and socially conscious bicycling community worldwide," remarked Chairman Pai of the CHC. "With the launch of the Handcycle and this pledge, we are setting the wheels in motion to realize this vision." "We envision a more accessible, inclusive, sustainable, and socially conscious bicycling community worldwide," remarked Chairman Pai of the CHC. "With the launch of the Handcycle and this pledge, we are…
PR Newswire
12/03/2024
Global Cell Penetrating Peptide Market to Reach $8.40 Billion by 2030 Owing To…
Market Dynamics: Market Dynamics: The Cell Penetrating Peptide Market is driven by the increasing demand for targeted drug delivery systems, as these peptides have the ability to penetrate cell membranes and deliver drugs directly to target cells. Additionally, the growing focus on personalized medicine and advancements in peptide synthesis technologies are further fueling market growth. Global Cell Penetrating Peptide Market Report Coverage • Increasing Pharmaceutical R&D...
PR Newswire
11/03/2024
medac unveils new Global Corporate Brand
The pharmaceutical company medac, founded in Germany in 1970, has evolved into an internationally renowned corporate group with two contract development and manufacturing organizations in Europe and a distribution to 91 countries. The focus of medac's work is on improving established pharmaceutical products as well as developing new therapeutics in four key areas rheumatology, urology, hematology, and oncology. After decades of impressive and successful growth, the company is now unveiling a...
Nasdaq GlobeNewswire
11/03/2024
Global Personal Protective Equipment Market to reach a valuation of US$ 69,169.3…
Download the Sample PDF report to explore key market insights and trends: Download the Sample PDF report to explore key market insights and trends: https://www.futuremarketinsights.com/reports/sample/rep-gb-1060 Adherence to regulatory compliance and certification standards remains a critical factor driving market growth. Manufacturers must ensure that their personal protection equipment products meet rigorous safety and quality standards established by regulatory authorities...
PR Newswire
11/03/2024
Pharmaceutical Membrane Filtration Market Worth $19.6 billion |…
Browse in-depth TOC on "Pharmaceutical Membrane Filtration Market" Browse in-depth TOC on "Pharmaceutical Membrane Filtration Market" 652 - Tables55 - Figures502 - Pages Pharmaceutical Membrane Filtration Market Scope: The polyethersulfone (PES) membrane filters segment accounted for the largest share of the membrane filters segment in the pharmaceutical membrane filtration market in 2023. Based on products, the pharmaceutical membrane filtration market is...
PR Newswire
11/03/2024
Regenerative Medicine's Influence on Amniotic Membrane Market Growth: Predicted…
Key aspects covered in the Amniotic Membrane Market Research Report include: Key aspects covered in the Amniotic Membrane Market Research Report include: Download the Sample PDF report to explore key market insights and trends:https://www.futuremarketinsights.com/reports/sample/rep-gb-5044 In recent years, amniotic membranes or products from them have become very popular because they are used more in regenerative medicine. They are a natural scaffold that the body accepts well,...
PR Newswire
11/03/2024
Hyperpigmentation Treatment Market to Reach $10.5 Billion, Globally, by 2032 at…
Request Sample of the Report on Hyperpigmentation Treatment Market Forecast - https://www.alliedmarketresearch.com/request-sample/A186336 Request Sample of the Report on Hyperpigmentation Treatment Market Forecast -https://www.alliedmarketresearch.com/request-sample/A186336 Prime determinants of growth The growth of the hyperpigmentation treatment market is driven by several factors such as rise in awareness about skin care, high impact of social media on beauty standards, and...
PR Newswire
11/03/2024
Novo Nordisk A/S - share repurchase programme
Bagsværd, Denmark, 11 March 2024– On 6 February 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 20 billion to be executed during a 12-month period beginning 6 February 2023. Under the...
Nasdaq GlobeNewswire
11/03/2024
Theriva™ Biologics to Participate in the BIO-Europe Spring Conference
BIO-Europe Spring ConferenceFormat: Corporate presentation and one-on-one meetings Presentation Date: Monday, March 18, 2024 Presentation Time: 3:00pm CET Presentation Location: Room 133/134, Barcelona International Convention Centre (CCIB) About Theriva™ Biologics, Inc. Theriva™ Biologics (NYSE American: TOVX), is a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need. The Company is advancing a new...
Nasdaq GlobeNewswire
11/03/2024
Hisense Showcases Leadership and Innovation at Air Conditioners Partners Meet…
In addition to showcasing the brand's latest air conditioner innovations, which reaffirmed Hisense's commitment to its four core business values of integrity, innovation, customer focus, and sustainability, Hisense presented its forward-looking strategic initiatives. The establishment of the AC Research and Development centre inDubaiunderscores Hisense's commitment to developing solutions tailored to meet the needs of the local market. This commitment to localised innovation will...
PR Newswire
11/03/2024
BioNTech to Present Clinical Data Updates for Personalized mRNA-based and…
MAINZ, Germany, March 11, 2024– BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will present clinical trial data for selected candidates from its oncology pipeline at the American Association for Cancer Research (“AACR”) Annual Meeting 2024 in San Diego, California, from April 5-10, 2024. The oral and poster presentations will feature BioNTech's investigational mRNA-based cancer vaccine and novel investigational antibody-drug conjugate (“ADC”) approaches.“This year's AACR...
Nasdaq GlobeNewswire
11/03/2024
Anyware Solutions' Morten Bremild named CEO of the Year for transformative…
Morten Bremild, CEO and Founder of Anyware Solutions, is working to transform the healthcare industry by using remote monitoring technology to offer peace of mind and improved quality of life for older people. Bremild's expertise in the sector is underlined by his achievement of CEO of the Year in the Remote Care Services Industry in European CEO's 2023 Awards. Morten Bremild, CEO and Founder ofAnyware Solutions, is working to transform the healthcare industry by using remote monitoring...
PR Newswire
11/03/2024
ColdZyme® certified under the new EU medical device regulation (MDR)
"This is an important milestone in the history of Enzymatica as the MDR certification validates our scientific data and creates great commercial opportunities for us. In addition, it increases the consumer confidence in ColdZyme® as well as opens up new markets. The certification is highly anticipated by our partners since it ensures long term security which will contribute to Enzymatica's growth," says Claus Egstrand, CEO of Enzymatica. "This is an important milestone in the…
PR Newswire
11/03/2024
Fortrea Signs Definitive Agreement to Divest Endpoint Clinical and Patient…
Proposed divestiture of Endpoint Clinical and Fortrea Patient Access businesses further streamlines Fortrea's strategic focus as a pure-play contract research organization Creates standalone best-in-class Randomization and Trial Supply Management and Patient Access solutions positioned for differentiation and growth DURHAM, N.C., March11, 2024(GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization (CRO), today announced it has...
Nasdaq GlobeNewswire
11/03/2024
Arthritic Therapeutic Market to Reach $ 136.1 billion, Globally, by 2032 at 5.5%…
Request Sample of the Report on Arthritic Therapeutic Market Forecast - https://www.alliedmarketresearch.com/request-sample/2571 Request Sample of the Report on Arthritic Therapeutic Market Forecast -https://www.alliedmarketresearch.com/request-sample/2571 Prime determinants of growth Factors such as technological advancements, rise in incidence of arthritic disorders & conditions, and surge in aging population drive the growth of the global arthritic therapeutic market...
PR Newswire
11/03/2024
Virbac : Declaration of the number of shares and voting rights 02/2024
DECLARATION OF THE NUMBER OF SHARES AND VOTING RIGHTS Information on the total number of voting rights and of shares representing the share capital (Article 223-16 of the General regulations of the French Financial Market Authority – Autorité des Marchés Financiers)Quotation place: Euronext Paris Compartiment A ISIN code: FR0000031577DateTotal number of shares representing the share capitalTotal number of voting rightsFebruary, 29 20248 458 000Gross total of voting...
Nasdaq GlobeNewswire
11/03/2024
Transactions in connection with share buy-back program
Company Announcement COPENHAGEN, Denmark; March 11, 2024 – Genmab A/S (Nasdaq: GMAB).On February 14, 2024, Genmab announced the initiation of a share buy-back program to honor our commitments under our Restricted Stock Units program.The share buy-back program is expected to be completed no later than March 15, 2024, and comprises up to 190,000 shares.The following transactions were executed under the program from February 26 to March 8, 2024: No. of sharesAverage price...
Nasdaq GlobeNewswire
11/03/2024
Major shareholder announcement – BlackRock, Inc.
ANNOUNCEMENT NO. 253Major shareholder announcementMajor shareholder announcement – BlackRock, Inc. Pursuant to Section 30 of the Capital Markets Act, it is hereby announced that BlackRock, Inc. has informed ChemoMetec A/S that BlackRock, Inc. on 7 March 2024, increased its holding of shares and voting rights in ChemoMetec A/S to 12.17% of the total share capital and voting rights, and that the holding thus exceeds the 10 per cent limit in section 38 of the Capital...
Nasdaq GlobeNewswire
11/03/2024
Flavonoid Market to Reach $2,926.7 million, Globally, by 2032 at 5.8% CAGR…
Download Free Sample Report: https://www.alliedmarketresearch.com/request-sample/A14262 Download Free Sample Report:https://www.alliedmarketresearch.com/request-sample/A14262 Prime determinants of growth Flavonoid is largely used in the nutraceuticals industry. This is attributed to the high consumption and demand for nutraceutical supplements containing flavonoids such as isoflavones and anthocyanidins, which in turn is driving the growth of the market. In addition, the...
PR Newswire
11/03/2024
ImmunAbs Announces Conclusion of Phase 1 Clinical Trial, Revealing Positive…
Dr. Dongjo Kim, the CEO of ImmunAbs, conveyed his excitement about the results, stating, "we are excited to share that the topline results are positive. In this trial, we assessed a critical biomarker for complement inhibition -- serum free C5 concentration -- confirming the efficacy of IM-101 in binding to C5 in humans. These outcomes lay a solid foundation for addressing the unmet medical needs of patients experiencing residual symptoms despite receiving the current standard of care. We…
PR Newswire
11/03/2024
2024 Collectibles Demand estimated at $594.2 Billion Revenue: Research by Market…
"Collectibles Market is estimated to reach $594.2 Billion by 2034. Grading and authentication services and tie-ups between collectible sellers and authenticating companies has witnessed a rise. The business arena of auction houses has proliferated and expanded to new sales channels. Trading and resale of collectibles and trading cards has created a huge secondary market in the U.S." "Collectibles Market is estimated to reach$594.2 Billionby 2034. Grading and authentication…
PR Newswire
11/03/2024
PulseCath Achieves MDR CE Certification for iVAC 2L, Paving the Way for Complex…
The iVAC 2L System is a percutaneous Mechanical Circulatory Support (MCS) device. It can be used to facilitate high-risk Percutaneous Coronary Interventions (PCIs). The main advantage of iVAC 2L is that it pumps blood from the left ventricle to the aorta, synchronizing with the natural rhythm of the patient's cardiac cycle. It enables to perform the intervention with a circulatory back-up that keeps the patient hemodynamically stable. The iVAC 2L System is a percutaneous Mechanical…
PR Newswire
11/03/2024
Recursion Announces Plans to Open New Office in London
Appoints Michael Bronstein as Scientific Advisor and launches recruiting effort to fill the first 20 open roles across technology and biology, establishing a hub for world-class TechBio talent in the heart of King's Cross neighborhood Recursion(Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced plans to open a new office in London's vibrant King's Cross neighborhood. Set to formally open in June 2024, the site will...
Nasdaq GlobeNewswire
11/03/2024
Altri Comunicati
